DYNAMO:Duvelisib(IPI-145)治疗难治性惰性非霍奇金淋巴瘤的II期研究
DYNAMO是一项开放标签全球II期试验,纳入129例对利妥昔单抗及化疗或放射免疫治疗双重难治的惰性非霍奇金淋巴瘤患者,口服Duvelisib 25 mg每日两次。总缓解率为47.3%(SLL 67.9%,FL 42.2%,MZL 38.9%),中位缓解持续时间约10个月,中位无进展生存期9.5个月,安全性可控。
要点
- 双重难治iNHL患者口服Duvelisib 25 mg每日两次,总缓解率47.3%。
- 亚组缓解率:SLL 67.9%,FL 42.2%,MZL 38.9%。
- 88.4%患者发生≥3级不良事件,最常见为中性粒细胞减少24.8%。
核心结论
- 口服Duvelisib单药在重度经治、双重难治的惰性非霍奇金淋巴瘤中显示出有临床意义的活性和可控的安全性,与既往观察一致。
- Duvelisib可能为该患者群体(许多为老年且需要额外治疗)提供新的口服治疗选择。
研究设计与样本
- 开放标签、全球、II期试验,纳入129例可测量惰性非霍奇金淋巴瘤(FL、SLL或MZL)且对利妥昔单抗(单药或联合)及化疗或放射免疫治疗双重难治的患者。
- 所有患者接受Duvelisib 25 mg口服每日两次,28天为一周期,直至疾病进展、不可接受毒性或死亡。
- 主要终点为总缓解率,采用修订的国际恶性淋巴瘤工作组标准。
主要发现
- 总缓解率为47.3%(SLL 67.9%,FL 42.2%,MZL 38.9%)。
- 估计中位缓解持续时间为10个月,估计中位无进展生存期为9.5个月。
- 任何级别治疗中出现的不良事件最常见为腹泻(48.8%)、恶心(29.5%)、中性粒细胞减少(28.7%)、乏力(27.9%)和咳嗽(27.1%)。
- 88.4%的患者至少发生一项≥3级治疗中出现的不良事件,最常见为中性粒细胞减少(24.8%)、腹泻(14.7%)、贫血(14.7%)和血小板减少(11.6%)。
关键数值与推荐
- 总缓解率47.3%(SLL 67.9%,FL 42.2%,MZL 38.9%)。
- 估计中位缓解持续时间10个月,估计中位无进展生存期9.5个月。
临床怎么用
- Duvelisib可能为重度经治、双重难治的惰性非霍奇金淋巴瘤患者(许多为老年且需要额外治疗)提供新的口服治疗选择。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Indolent non-Hodgkin lymphoma (iNHL) remains largely incurable and often requires multiple lines of treatment after becoming refractory to standard therapies. Duvelisib was approved by the Food and Drug Administration for relapsed or refractory (RR) chronic lymphocytic leukemia or small lymphocytic lymphoma (SLL) and RR follicular lymphoma (FL) after two or more prior systemic therapies. On the basis of the activity of duvelisib, a first-in-class oral dual inhibitor of phosphoinositide 3-kinase-δ,-γ, in RR iNHL in a phase I study, the safety and efficacy of duvelisib monotherapy was evaluated in iNHL refractory to rituximab and either chemotherapy or radioimmunotherapy. PATIENTS AND METHODS: Eligible patients had measurable iNHL (FL, SLL, or marginal zone B-cell lymphoma) double refractory to rituximab (monotherapy or in combination) and to either chemotherapy or radioimmunotherapy. All were treated with duvelisib 25 mg orally twice daily in 28-day cycles until progression, unacceptable toxicity, or death. The primary end point was overall response rate (ORR) using the revised International Working Group criteria for malignant lymphoma. RESULTS: This open-label, global phase II trial enrolled 129 patients (median age, 65 years; median of three prior lines of therapy) with an ORR of 47.3% (SLL, 67.9%; FL, 42.2%; MZL, 38.9%). The estimated median duration of response was 10 months, and the estimated median progression-free survival was 9.5 months. The most frequent any-grade treatment-emergent adverse events (TEAEs) were diarrhea (48.8%), nausea (29.5%), neutropenia (28.7%), fatigue (27.9%), and cough (27.1%). Among the 88.4% of patients with at least one grade 3 or greater TEAE, the most common TEAEs were neutropenia (24.8%), diarrhea (14.7%), anemia (14.7%), and thrombocytopenia (11.6%). CONCLUSION: In the DYNAMO study, oral duvelisib monotherapy demonstrated clinically meaningful activity and a manageable safety profile in heavily pretreated, double-refractory iNHL, consistent with previous observations. Duvelisib may provide a new oral treatment option for this patient population of which many are elderly and in need of additional therapies.
引用
- Flinn IW, Miller CB, Ardeshna KM, et al. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. J Clin Oncol. 2019. PMID: 30742566. doi:10.1200/JCO.18.00915
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。